TD Cowen analyst Tyler Van Buren has maintained their bullish stance on APGE stock, giving a Buy rating on March 4.
Tyler Van Buren has given his Buy rating due to a combination of factors, primarily centered around Apogee Therapeutics’ promising clinical data and strategic pipeline developments. The company has shown impressive results with its Phase I data for APG990 and is leading with APG777, which has demonstrated strong potential in its Phase II trials. The confidence in APG777 is bolstered by its product-in-a-pipeline potential, similar to Dupi, with upcoming trials for asthma and EoE expected in 2025-2026.
Additionally, the updated Phase I data for APG777, which incorporates YTE half-life extension technology, showed an increased half-life and significant pSTAT6 durability, suggesting potential for annual dosing. The anticipation of positive Phase II data for AD patients mid-2025 further supports the Buy rating, as the company aims to achieve efficacy on par with standard therapies but with improved dosing. These factors collectively indicate a strong growth trajectory for Apogee Therapeutics, justifying the Buy recommendation.
According to TipRanks, Van Buren is an analyst with an average return of -2.2% and a 39.92% success rate. Van Buren covers the Healthcare sector, focusing on stocks such as Regeneron, BridgeBio Pharma, and Arcutis Biotherapeutics.
In another report released on March 4, Bank of America Securities also maintained a Buy rating on the stock with a $80.00 price target.